CÁNCER DE PRÓSTATA OLIGOMETASTÁSICO: El papel de la radioterapia - page 49

www.clinicaltrials.gov
Study iden fier Study type Pa ent popula on Popula on/ Interven on N Primary endpoint Secondary endpoints
NCT01777802
Mayo Clinic
Observa onal
, prospec ve
Oligometasta c (4)
amen.to SABR
Monitor an -Pca immunity
following SABR 20 Induc on of
an prostate cancer
immunity
Not reported
NCT0256391
Toronto U
Phase I/II,
non
randdomized
Oligometasta c CS
(<5)
SABR, AD (intermi ent
HT allowed a er 1 y)
30 Rate of late
radiotherapy
toxicity
QOL, me to CR,LC,
Distant control, OS.
NCT01859221
University of
Florida
Phase II, non
randomized
CS or CRPC
oligometasta c
SABR/SHRT 48 PFS 78m OS, treatment
failure rate; QOL
NCT01558427
Ghent U
Phase II,
randomized,
open label
Low volume
Oligorecurrent CS, ≤3,
Arm 1: ac ve
surveillance Arm 2:
(surgery or SBRT)
54 ADT-free survival QOL
NCT02264379
Dresden U
Observa onal
, prospec ve
Oligomet. CS
oligorrec. (1–5)
Arm 1:5x5Gy
Arm2:3x10Gy
60 Toxicity (24 mo) Acute toxicity, QOL,
LC, TFS, PSAFS
NCT02192788
SBRT-SG 05
GICOR
Phase II,
nonrandomized
oligorecurrent, <5
bone or lymph node
SABR 68 PFS (5 y) OS; toxicity;TCT,
QOL.
NCT02685397
Jewish General
Hosp
Phase II/III
randomized
oligorecurrent, <5 bone
or lymph node visceral
Arm 1:HT+Enza
Arm2:HT+Enza+SBRT
65 PFSr QOL,Toxicity, LC,
TCT
LC